Krebber AMH, Buffart LM, Kleijn G, Riepma IC, de Bree R, Leemans CR, et al. Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. Psychooncology. 2014;23:121–30.
Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12:160–74.
Lu D, Andersson TM, Fall K, Hultman CM, Czene K, Valdimarsdottir U, et al. Clinical diagnosis of mental disorders immediately before and after cancer diagnosis: a nationwide matched cohort study in Sweden. JAMA Oncol. 2016;2:1188–96.
Burgess C, Cornelius V, Love S, Graham J, Richards M, Ramirez A. Depression and anxiety in women with early breast cancer: five year observational cohort study. BMJ. 2005;330:702.
Gotze H, Friedrich M, Taubenheim S, Dietz A, Lordick F, Mehnert A. Depression and anxiety in long-term survivors 5 and 10 years after cancer diagnosis. Support Care Cancer. 2019;28:211–20.
Walker J, Hansen CH, Martin P, Symeonides S, Ramessur R, Murray G, et al. Prevalence, associations, and adequacy of treatment of major depression in patients with cancer: a cross-sectional analysis of routinely collected clinical data. Lancet Psychiatry. 2014;1:343–50.
Wu HS, Harden JK. Symptom burden and quality of life in survivorship: a review of the literature. Cancer Nurs. 2015;38:E29-54.
Mehnert A, de Boer A, Feuerstein M. Employment challenges for cancer survivors. Cancer. 2013;119(Suppl. 11):2151–9.
Naughton MJ, Weaver KE. Physical and mental health among cancer survivors: considerations for long-term care and quality of life. N C Med J. 2014;75:283–6.
Colleoni M, Mandala M, Peruzzotti G, Robertson C, Bredart A, Goldhirsch A. Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet. 2000;356:1326–7.
Mausbach BT, Schwab RB, Irwin SA. Depression as a predictor of adherence to adjuvant endocrine therapy (AET) in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2015;152:239–46.
Zhou T, Duan JJ, Zhou GP, Cai JY, Huang ZH, Zeng YT, et al. Impact of depression mood disorder on the adverse drug reaction incidence rate of anticancer drugs in cancer patients. J Int Med Res. 2010;38:2153–9.
Fang F, Fall K, Mittleman MA, Sparen P, Ye W, Adami HO, et al. Suicide and cardiovascular death after a cancer diagnosis. N Engl J Med. 2012;366:1310–8.
Pinquart M, Duberstein PR. Depression and cancer mortality: a meta-analysis. Psychol Med. 2010;40:1797–810.
Yamauchi T, Inagaki M, Yonemoto N, Iwasaki M, Inoue M, Akechi T, et al. Death by suicide and other externally caused injuries following a cancer diagnosis: the Japan Public Health Center-based Prospective Study. Psychooncology. 2014;23:1034–41.
Fallowfield L, Ratcliffe D, Jenkins V, Saul J. Psychiatric morbidity and its recognition by doctors in patients with cancer. Br J Cancer. 2001;84:1011–5.
Walker J, Sawhney A, Hansen CH, Ahmed S, Martin P, Symeonides S, et al. Treatment of depression in adults with cancer: a systematic review of randomized controlled trials. Psychol Med. 2014;44:897–907.
Wang PS, Angermeyer M, Borges G, Bruffaerts R, Tat Chiu W, De Girolamo G, et al. Delay and failure in treatment seeking after first onset of mental disorders in the World Health Organization’s World Mental Health Survey Initiative. World Psychiatry. 2007;6:177–85.
Ishikawa H, Kawakami N, Kessler RC, World Mental Health Japan Survey Collaborators. Lifetime and 12-month prevalence, severity and unmet need for treatment of common mental disorders in Japan: results from the final dataset of World Mental Health Japan Survey. Epidemiol Psychiatr Sci. 2016;25:217–29.
Kanehara A, Umeda M, Kawakami N, World Mental Health Japan Survey Group. Barriers to mental health care in Japan: results from the World Mental Health Japan Survey. Psychiatry Clin Neurosci. 2015;69:523–33.
American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder, 3rd edition. 2010. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. Accessed 1 June 2020.
Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Moller HJ, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013;14:334–85.
Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015;29:459–525.
Committee for Treatment Guidelines of Mood Disorders, Japanese Society of Mood Disorders. II. Guidelines for treatment of depression (DSM-5)/major depression disorder [in Japanese]. 2016. https://www.secretariat.ne.jp/jsmd/iinkai/katsudou/data/160731.pdf. Accessed 1 June 2020.
Furukawa TA, Maruo K, Noma H, Tanaka S, Imai H, Shinohara K, et al. Initial severity of major depression and efficacy of new generation antidepressants: individual participant data meta-analysis. Acta Psychiatr Scand. 2018;137:450–8.
Miguel C, Albuquerque E. Drug interaction in psycho-oncology: antidepressants and antineoplastics. Pharmacology. 2011;88:333–9.
Smith HR. Depression in cancer patients: pathogenesis, implications and treatment (review). Oncol Lett. 2015;9:1509–14.
Akechi T, Mishiro I, Fujimoto S, Murase K. Risk of major depressive disorder in Japanese cancer patients: a matched cohort study using employer-based health insurance claims data. Psychooncology. 2020. https://doi.org/10.1002/pon.5509.
ICD. International Statistical Classification of Diseases and Related Health Problems, 10th Revision. 2016. https://icd.who.int/browse10/2016/en. Accessed 1 June 2020.
Ministry of Health, Labour and Welfare. Ethical guidelines for medical and health research involving human subjects. 2015. https://www.mhlw.go.jp/file/06-Seisakujouhou-10600000-Daijinkanboukouseikagakuka/0000080278.pdf. Accessed 1 June 2020.
Uchida H, Takeuchi H, Suzuki T, Nomura K, Watanabe K, Kashima H. Combined treatment with sulpiride and paroxetine for accelerated response in patients with major depressive disorder. J Clin Psychopharmacol. 2005;25:545–51.
Okamura M, Akizuki N, Nakano T, Shimizu K, Ito T, Akechi T, et al. Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer. Psychooncology. 2008;17:154–60.
van Marwijk H, Allick G, Wegman F, Bax A. Riphagen, II. Alprazolam for depression. Cochrane Database Syst Rev. 2012;7:CD007139.
Li M, Fitzgerald P, Rodin G. Evidence-based treatment of depression in patients with cancer. J Clin Oncol. 2012;30:1187–96.
Grassi L, Nanni MG, Rodin G, Li M, Caruso R. The use of antidepressants in oncology: a review and practical tips for oncologists. Ann Oncol. 2017;29:101–11.
Suzuki S, Kawasumi K, Ichida Y, Fujisawa D, Ogawa A, Watanabe K, et al. Survey on opioid and psychotic use by cancer patients [in Japanese]. Jpn J Pharm Health Care Sci. 2011;37:437–41.
Wilson S, Nutt D. Management of insomnia: treatments and mechanisms. Br J Psychiatry. 2007;191:195–7.
Fisch MJ, Zhao F, Manola J, Miller AH, Pirl WF, Wagner LI. Patterns and predictors of antidepressant use in ambulatory cancer patients with common solid tumors. Psychooncology. 2015;24:523–32.
Sato I, Onishi H, Yamada S, Kawakami K. Prevalence and initial prescription of psychotropics in patients with common cancers in Japan, based on a nationwide health insurance claims database. Psychooncology. 2018;27:450–7.
Sanjida S, Janda M, Kissane D, Shaw J, Pearson SA, DiSipio T, et al. A systematic review and meta-analysis of prescribing practices of antidepressants in cancer patients. Psychooncology. 2016;25:1002–16.
Wong E, Bedard G, Pulenzas N, Lechner B, Lam H, Thavarajah N, et al. Gender differences in symptoms experienced by advanced cancer patients: a literature review. Rev Health Care. 2013;4:141–53.
Sharma M, Loh KP, Nightingale G, Mohile SG, Holmes HM. Polypharmacy and potentially inappropriate medication use in geriatric oncology. J Geriatr Oncol. 2016;7:346–53.
Tedeschini E, Levkovitz Y, Iovieno N, Ameral VE, Nelson JC, Papakostas GI. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry. 2011;72:1660–8.
Tamblyn R, Bates DW, Buckeridge DL, Dixon W, Forster AJ, Girard N, et al. Multinational comparison of new antidepressant use in older adults: a cohort study. BMJ Open. 2019;9:e027663.
Akechi T, Furukawa TA. Depressed with cancer can respond to antidepressants, but further research is needed to confirm and expand on these findings. Evid Based Ment Health. 2015;18:28.